Please check your internet connection and try again.
# Arsil dx (Dextromethorphan/Chlorpheniramine/Phenylephrine)
## Overview
Arsil DX is a common multi-ingredient over-the-counter (OTC) combination product containing an antitussive (dextromethorphan), a first-generation antihistamine (chlorpheniramine), and a sympathomimetic decongestant (phenylephrine).
## Primary Indications
Symptomatic relief of cough, upper respiratory congestion, and rhinorrhea associated with the common cold or allergic rhinitis.
## Adult Dosing
Standard formulation: 10–20 mg dextromethorphan / 2–4 mg chlorpheniramine / 10 mg phenylephrine every 4 to 6 hours as needed.
Maximum: Do not exceed 4 doses in 24 hours.
## Pediatric Dosing
* **Children < 4 years:** Generally avoided due to lack of efficacy and high risk of overdose; consult local pediatric guidelines.
* **Children 4–6 years:** Use only if directed by a physician.
* **Children 6–12 years:** 5–10 mg dextromethorphan / 1–2 mg chlorpheniramine / 5 mg phenylephrine every 4 to 6 hours as needed. Maximum: 4 doses/24 hours.
* **Adolescents (≥12 years):** Same as adult dosing.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No standard adjustments, but use with caution in patients with severe impairment; reduced frequency is often recommended due to potential accumulation.
* **Geriatrics:** High risk of anticholinergic effects (e.g., urinary retention, sedation, confusion) from chlorpheniramine; use with extreme caution or avoid (Beers Criteria).
## Contraindications
* Hypersensitivity to any component.
* Concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI (risk of hypertensive crisis/serotonin syndrome).
* Severe hypertension or severe coronary artery disease.
## Adverse Effects
* **Common:** Drowsiness, dizziness, dry mouth, blurred vision, thick bronchial secretions.
* **Serious:** Tachycardia, hypertension, urinary retention, paradoxical excitation in children, serotonin syndrome (if interacting agents are present).
## Key Drug Interactions
* **MAOIs:** Absolute contraindication; life-threatening hypertensive or serotonergic reactions.
* **CNS Depressants (Alcohol, Opioids, Benzodiazepines):** Potentiates sedation; avoid combined use.
* **Antihypertensives:** Phenylephrine may antagonize the effects of certain bp medications.
## Monitoring
* Monitor blood pressure and heart rate, especially in patients with pre-existing cardiovascular conditions.
* Monitor for signs of urinary retention or sedation.
* Assess cough/congestion severity; discontinue if symptoms persist beyond 7 days or are accompanied by high fever.
## Clinical Pearls
* **First-Generation Antihistamines:** Chlorpheniramine's sedation profile is significant; counsel patients on driving and operating machinery.
* **Phenylephrine Efficacy:** Note that oral phenylephrine is widely recognized in current clinical literature (and by FDA advisory committees) to have questionable efficacy as a decongestant at standard oral doses.
* **Avoid "Double-Dosing":** Ensure patients are not taking multiple multi-symptom products simultaneously to prevent accidental toxicity of shared ingredients.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practices vary by institution and region. Always consult the most current drug monograph, package insert, and your local institutional guidelines before prescribing or administering medication.
